Roles of mitochondrial transcription factor A and microRNA-590-3p in the development of bladder cancer

MIAO MO¹, FENGHUA PENG¹, LU WANG², LONGKAI PENG¹, GONGBIN LAN¹ and SHAOJIE YU¹

¹Department of Urologic Organ Transplantation, The Second Xiangya Hospital of Central South University;
²Department of Otolaryngology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China

Received December 21, 2012; Accepted June 13, 2013

DOI: 10.3892/ol.2013.1419

Abstract. Mitochondrial transcription factor A (TFAM) is required for mitochondrial DNA (mtDNA) replication and transcription. microRNAs (miRNAs) act as key factors in the regulation of gene expression. However, the roles of TFAM and certain miRNAs and their association in cancer development remain unclear. The present study reported that the expression of TFAM was significantly increased in bladder cancer, while the expression of miRNA-590-3p was downregulated. The luciferase assay showed that TFAM was the direct target of miRNA-590-3p. Furthermore, the forced overexpression of miRNA-590-3p significantly inhibited the proliferation, migration and colony-forming ability of 5637 cells, which was in contrast with the results from the forced overexpression of TFAM in the 5637 cells. Furthermore, cell proliferation- and migration-related genes, including phosphoinositide-3-kinase (PI3K), Akt, matrix metalloproteinase (MMP)-2 and MMP9, were significantly downregulated in the miRNA-590-3p-overexpressing 5637 cells, but upregulated in the TFAM-overexpressing cells. In conclusion, the present study suggested that TFAM, a direct target of miRNA-590-3p, may play a significant role in the tumorigenesis of bladder cancer and thus may be a promising target for cancer therapeutics.

Introduction

Mitochondrial transcription factor A (TFAM), a member of the high mobility group (HMG) box protein family, is required for mitochondrial DNA (mtDNA) replication and transcription. HMG proteins are often overexpressed in cancer cells and are involved in apoptosis (1). Furthermore, mitochondria are critical for cancer cell metabolism. Mitochondrial uncoupling regulates the metabolic shift to aerobic glycolysis, which is termed the Warburg Effect and is essential for the survival and proliferation of cancer cells (2,3). As a result, mitochondria are involved in the regulation of cancer cell survival and growth.

Bladder cancer is the most prevalent form of cancer among males. Urinary bladder cancers are detected in 3.71% of elderly males in the USA, indicating that the cancer is associated with aging and oxidative stress (4). The high expression of TFAM has been reported to be related with a poor prognosis in multiple malignant tumors, including ovarian cancer, endometrial carcinoma and colon cancer (5-7). TFAM is expressed not only in mitochondria, but also in nuclei (7). Furthermore, as well as being a transcription factor in mitochondria, TFAM also regulates the expression of nuclear genes. It has been reported that the number of mitochondria correlates with the growth rate of cancer cells and that the TFAM protein multimerizes and binds to mtDNA, suggesting that the TFAM levels may be increased in cancer cells and be associated with the malignant progression and proliferative activity (8). However, the roles of TFAM have not been fully identified in cancer cells.

microRNAs (miRNAs) are small, endogenous and non-coding RNAs that inhibit gene expression via the interaction with target sites in the 3'-untranslated regions (UTRs) of mRNA (9). miRNAs play significant roles in regulating multiple biological processes, including the pathogenesis of a variety of human cancers (10-12). miR-590-3p has been reported to be involved in mediating the expression of autoimmune genes and neuronal death (13,14). However, whether or not miR-590-3p is associated with malignant tumors remains unclear.

The present study aimed to elucidate the roles of TFAM and miR-590-3p and their association in bladder cancer cells.

Materials and methods

Cell culture. The human bladder carcinoma 5637 cell line (Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, China) was cultured in RPMI-1640 medium with 10% FBS and 1% penicillin/streptomycin at 37°C, with 5% CO₂.

RNA extraction and quantitative (q)PCR analysis. RNA was extracted from the tissues or cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. The RNA integrity was then assessed. A TaqMan qRT-PCR miRNA assay (Applied Biosystem, Carlsbad, CA, USA) was performed to detect
the mature miR-590-3p expression levels. The relative expression of mature miR-590-3p levels normalized to U6 endogenous control was determined using the 2^ΔΔCt method. Each measurement was performed in triplicate. To detect the target genes (mRNA expression), 1 μg total RNA was reverse transcribed to cDNA using SuperScript™ III First-Strand Synthesis SuperMix (Invitrogen). For TFAM expression, SYBR Green qPCR Mix (Toyobo, Osaka, Japan) was used. SYBR green q-PCR was performed using the Bio-Rad iQ5 PCR detection system (Bio-Rad, Hercules, CA, USA) with the following gene-specific primers: forward, 5'-AAAGATTCCAAGAAGCTAAGGGTG-3' and reverse, 5'-CCTAACTGGTTTCTCTGCTCTA-3'.

Western blotting. The cells were solubilized in cold RIPA lysis buffer and then separated with 10% SDS-PAGE. Following this, the proteins were transferred to PVDF membranes. The membranes were blocked in 5% skimmed dried milk in PBS for 1 h and then incubated overnight with primary antibodies for TFAM (rabbit polyclonal), Akt (rabbit polyclonal), p-Akt (rabbit polyclonal), matrix metalloproteinase (MMP)-2 (mouse monoclonal), MMP-9 (rabbit polyclonal) (Abcam, San Francisco, CA, USA), phosphatidylinositol-3-kinase (PI3K; rabbit polyclonal), p-PI3K (rabbit polyclonal) and β-actin (mouse monoclonal) (Abzoom Biolabs, Dallas, TX, USA). Subsequent to being incubated with goat polyclonal antibody and goat anti-mouse secondary antibodies (Abcam), the immune complexes were detected using the enhanced chemiluminescence (ECL) method. The results were visualized by autoradiography using preflashed Kodak XAR film (Kodak, Tokyo, Japan).

Dual Luciferase reporter assays. To generate the reporter vectors bearing miRNA-binding sites, a normal and mutated 3'–UTR of TFAM was subcloned using PCR-based methods. The constructs were inserted into the multiple cloning sites downstream of the luciferase gene in the psiCHECK-2 luciferase miRNA expression reporter vector.

For the luciferase assay, 10^5 cells were cultured to ~70-80% confluence in 24-well plates and cotransfected with pSCEHECK-2-TFAM-3'-UTR or pSCEHECK2-mut-TFAM-3'-UTR vector plus 50 nM miR-590-3p or 100 mM miR-590-3p inhibitor using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s instructions. The cells were incubated with transfection reagent/DNA complex for 5 h and refreshed with fresh medium containing 10% FBS. At 48 h post-transfection, firefly and renilla luciferase activities were evaluated using the dual-luciferase reporter assay system (Promega) and the renilla luciferase activity was normalized to firefly luciferase activity.

Plasmid construction and transfection. TFAM, miR-590-3p and scramble miRNA [miR-SCR; negative control (NC)] plasmids were obtained from Auragene Bio (Changsha, China). The retroviral supernatants were prepared using Eco-Pheonix packaging cells and the 5673 cells were transduced using 20 mg/ml polybrene over 48 h.

Colonization formation assay. The colony formation rate was measured by a plate colony formation assay. In total, ~200 cells were added to each well of a 6-well plate. The plates were incubated at 37°C for 14 days and gently washed and stained with crystal violet. Viable colonies that contained at least 50 cells were counted.

Flow cytometric analyses. For the apoptosis analysis, 2x10^5 cells were collected, washed twice with PBS and resuspended in 400 μl 1X binding buffer. According to the manufacturer’s instructions, 5 μl Annexin V-FITC and propidium iodide (PI) solution was then added. The samples were incubated for 15 min at room temperature and analyzed using flow cytometry (FACSCalibur; Beckman Coulter, High Wycombe, UK).

For the cell cycle analysis, the cells were collected in 1X PBS and resuspended in 70% ethanol to fix overnight at -20°C. The cells were pelleted, washed twice in 3% BSA in 1X PBS and pelleted again. The cells were resuspended and incubated for 30 min at room temperature in a PI staining buffer containing 3% BSA, 40 μg/ml PI and 0.2 mg/ml RNase in 1X PBS. DNA content analyses were carried out using flow cytometry (FACSCalibur; Beckman Coulter).

Transwell. For all the groups, migration was measured in 24-well Transwell chambers (Chemicon, Rosemont, IL, USA). Following a 24-h incubation period at 37°C, the migrated cells were stained with 0.04% trypan blue and counted with x200 magnification.

Statistical analysis. The data are shown as the mean ± SD of at least three determinations. The two-sided Student's t-test was used to analyze the differences in the experiments. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were conducted using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA).

Results

Protein expression of TFAM in the various tissues. To investigate the association between TFAM and bladder cancer, the expression of TFAM was first detected in normal, adjacent and bladder cancer tissues. As shown in Fig. 1, the expression of TFAM in the bladder cancer tissues was significantly higher compared with the normal and adjacent tissues (P<0.05). Furthermore, the tissues of the various cancer stages showed differing expression levels of TFAM. The expression of TFAM was at its highest in stage IIb tissues, whereas its expression in stage Ib tissues was the lowest.

Expression of miR-590-3p in the various tissues. The expression of miR-590-3p was then determined in the normal, adjacent and bladder cancer tissues. As shown in Fig. 2, the bladder cancer tissues showed a lower expression of miR-590-3p...
compared with the normal and adjacent tissues (P<0.05). Furthermore, miR-590-3p displayed different expression levels in the various stages of bladder cancer. The expression in the stage Ib tissues was the highest, whereas the expression in the stage IIb tissues was the lowest (P<0.05). However, in the normal and adjacent tissues, the expression of miR-590-3p was not significantly different (P>0.05).

**Luciferase assay of miR-590-3p.** A luciferase assay was performed to detect if TFAM was the direct target of miR-590-3p. The data showed that the renilla/firefly value of luciferase was significantly lower in the miR-590-3p treatment cells following transfection with the 3'UTR of the TFAM gene, while the renilla/firefly value of luciferase showed no difference following transfection with the mutated 3'UTR of TFAM compared with the control (Fig. 3). These data suggested that miR-590-3p may downregulate TFAM gene expression and that the 3'UTR of TFAM is the target of miR-590-3p.

**Detection of miR‑590‑3p and TFAM following transfection.** The data showed that the miR-590-3p expression level was significantly higher in the 5637 cells that were transfected with miR-590-3p lentiviral vectors compared with the controls (P<0.05; Fig. 4A). As shown in Fig. 4B, the expression of TFAM in the 5637 cells was upregulated following transfection with the TFAM overexpression plasmid compared with the controls (P<0.05; Fig. 4B). No significant differences were observed between the expression of TFAM in the control cells and the cells that were transfected with the NC virus (P>0.05).

**Effect of miR-590-3p and TFAM overexpression on the proliferation of 5637 cells.** As the expression level of miR-590-3p was lower in the bladder cancer tissues and the expression of TFAM was higher, the effect of the transfection of miR-590-3p and TFAM on 5637 cell proliferation was studied using MTT assays. The data showed significant cell growth inhibition in the miR-590-3p transfectant compared with the control from the 5367 cell lines. In contrast, the TFAM transfectant displayed a positive effect on cell growth (Fig. 5).
Effect of miR-590-3p and TFAM overexpression on the cell cycle of 5637 cells. As shown in Fig. 6, the cells that were transfected with the various vectors showed differences in the percentage of cells in the varying phases of the cell cycle. The cells that were transfected with miR-590-3p lentiviral vectors showed the highest percentage of cells in the G2 phase, suggesting that mitosis was blocked. For the cells transfected with TFAM overexpression vectors, the majority were in the G1 and S phases and only a few cells were in the G2 phase, indicating that cell division was active. These results indicated that TFAM promoted the mitosis of the 5637 cells, while miR-590-3p suppressed it.

Figure 5. Effect of miR-590-3p and TFAM overexpression on the proliferation of 5637 cells. MTT was performed to determine the effect of the forced overexpression of miR-590-3p and TFAM on the proliferation of the 5637 cells. Con, normal 5637 cells; scramble miR (miR-SCR), 5637 cells that were transfected with miR-SCR lentiviral vectors; miR-590-3p, 5637 cells that were transfected with miR-590-3p lentiviral vectors; TFAM, 5637 cells that were transfected with mitochondrial transcription factor A (TFAM) lentiviral vectors; miR, microRNA.

Figure 6. Effect of miR-590-3p and TFAM overexpression on the cell cycle of 5637 cells. A cell cycle assay was performed to determine the effect of the forced overexpression of miR-590-3p and TFAM on the cell cycle of 5637 cells. Con, normal 5637 cells; scramble miR (miR-SCR), 5637 cells transfected with miR-SCR lentiviral vectors; miR-590-3p, 5637 cells transfected with miR-590-3p lentiviral vectors; TFAM, 5637 cells transfected with mitochondrial transcription factor A (TFAM) lentiviral vectors; miR, microRNA.

Figure 7. Effect of miR-590-3p and TFAM overexpression on the migration of 5637 cells. A Transwell assay was performed to determine the effect of the forced overexpression of miR-590-3p and TFAM on the migration of 5637 cells. Top panel, trypan blue staining; magnification, x200. Con, normal 5637 cells; scramble miR (miR-SCR), 5637 cells transfected with miR-SCR lentiviral vectors; miR-590-3p, 5637 cells transfected with miR-590-3p lentiviral vectors; TFAM, 5637 cells transfected with mitochondrial transcription factor A (TFAM) lentiviral vectors. *P<0.05 vs. control. miR, microRNA.

Figure 8. Effect of miR-590-3p and TFAM overexpression on the colony-formation efficiency of 5637 cells. A clone-formation assay was performed to determine the effect of forced overexpression of miR-590-3p and TFAM on colony-formation efficiency of 5637 cells. Con, normal 5637 cells; NC, cells transfected with NC virus; miR-590-3p, 5637 cells transfected with miR-590-3p lentiviral vectors; TFAM, 5637 cells transfected with TFAM lentiviral vectors. *P<0.05 vs. control. miR, microRNA; TFAM, mitochondrial transcription factor A; NC, negative control.
Effect of miR-590-3p and TFAM overexpression on the migration of 5637 cells. As shown in Fig. 7, the overexpression of TFAM significantly promoted cell migration, while the miR-590-3p groups had the lowest migration level among all the groups. In addition, a histological analysis revealed no significant difference between the control and miR-SCR groups.

Discussion

miRNAs represent a class of snRNAs that have central roles in gene silencing and function as part of large gene regulatory networks (15). In animals, miRNAs hybridize to partially complementary binding sites that are typically located in the 3-UTR of target mRNAs and repress their expression (16). Recently, miRNAs were identified to have significant roles in tumorigenesis (15). Previous studies have demonstrated that certain miRNAs are significantly deregulated in bladder cancer and may function as tumor suppressors (17,18). However, the role of miRNA-159-3p in the development of bladder cancer remains unknown. The present study reported that the expression of miRNA-159-3p was decreased in bladder cancer tissues compared with normal and adjacent tissues. Furthermore, the data showed that the higher the cancer grade, the lower the miRNA-159-3p expression in the bladder cancer tissues.

TFAM was first purified and cloned as a transcription factor for mtDNA. TFAM is able to enhance mtDNA transcription using mitochondrial RNA polymerase in a promoter-specific fashion (19). Since the replication of mammalian mtDNA is proposed to be coupled with transcription, TFAM is thought to be essential for the replication of mtDNA (20). It has been reported that TFAM may function to promote cell survival and proliferation. TFAM-null mice have been demonstrated to possess an embryonic lethal phenotype and exhibit apoptosis in heart cells (21). The knockdown of TFAM expression has been shown to induce p21-dependent G1 cell cycle arrest (22). Indeed, the present data showed that in bladder cancer, the expression of TFAM was significantly higher compared with the normal and adjacent tissues, indicating that TFAM may be associated with the growth of bladder cancer.
Notably, the expression of miRNA-159-3p and TFAM in cancer tissues was shown to be negatively correlated, which indicated that miRNA-159-3p may inhibit the expression of TFAM. The results of the luciferase assay demonstrated that miRNA-159-3p was able to directly downregulate TFAM expression, whereas the mutated miRNA-159-3p did not. The present data demonstrated that TFAM is the direct target of miRNA-159-3p. To the best of our knowledge, there has been no earlier study reporting the interaction between TFAM expression and these particular miRNAs. The cause of TFAM overexpression is unknown, but one possible mechanism is through the regulation by miRNAs. The loss of miRNA-159-3p, the endogenous TFAM inhibitor, may promote the aberrant expression of TFAM, contributing to the pathogenesis and progression of bladder cancer.

Furthermore, the present study investigated the molecular function of miR-590-3p and TFAM in the bladder cancer 5637 cell line. The MTT data showed that TFAM transfection significantly promoted cell proliferation in the 5637 cells, while miR-590-3p markedly decreased the level of cell proliferation. A previous study demonstrated that TFAM in the colorectal carcinoma cell line RKO carrying a TFAM truncating mutation suppressed cell proliferation and inhibited RKO cell-induced xenograft tumor growth (23). miR-590-3p suppressed the growth rate of the 5637 cells in the present study. The cell cycle results showed that the 5637 cells that were transfected with miR-590-3p had the highest percentage of cells in the G1 phase and the lowest percentage of cells in the S and G2 phases. For the 5637 cells that were transfected with TFAM overexpression vectors, the majority were in the S and G2 phases and only a few were in the G1 phase. To detect the molecular regulatory pathway of miR-590-3p and TFAM in the 5637 cells, western blotting was performed to determine the protein expression of PI3K, p-PI3K, Akt, p-Akt, MMP2 and MMP9 after the forced overexpression of miR-590-3p or TFAM. TFAM transfection significantly promoted PI3K, p-PI3K, Akt, p-Akt, MMP2 and MMP9 protein expression. In contrast, miR-590-3p showed significant deregulation of protein expression of PI3K, p-PI3K, Akt, p-Akt, MMP2 and MMP9. Metastasis is a complex and multi-step dispersion process of malignant tumor cells from the primary tumor site to a secondary site within the body. Therefore, the activation of the zinc-binding endopeptidases, the MMPs, is considered to play a crucial role in the process of cancer invasion and metastasis (24). MMPs are primarily regulated at the transcriptional level through AP-1 or NF-kB via mitogen-activated protein kinase (MAPK) or PI3K-Akt pathways, at post-transcriptional levels, at the protein level via their activators or inhibitors or at their cell surface localization (25-27). The overexpression of MMP-2 and MMP-9 in malignant tumors has been demonstrated to develop a vasculature by angiogenesis (28). In the present study, TFAM was shown to be able to promote this pathway, miR-590-3p was able to downregulate TFAM expression. Thus, the deregulatory effect of miR-590-3p on the pathway should be associated with TFAM.

In summary, the present study identified miR-590-3p and TFAM transfection expression patterns in bladder cancer. Using the luciferase assay, TFAM was identified as a target of miR-590-3p. The study was also extended into the molecular functions of miR-590-3p and TFAM. miR-590-3p was able to deregulate the metastasis pathway and may be used a new target for the therapy of bladder cancer.

References

1. Krynetskaia NF, Phadke MS, JadHAV SH and Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDLA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther 8: 864-872, 2009.
2. Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements for cancer proliferation. Science 324: 1029-1033, 2009.
3. Ponomovskiy MR: Warburg effect mechanism as the target for theoretical substantiation of a new potential cancer treatment. Crit Rev Eukaryot Gene Expr 21: 13-28, 2011.
4. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
5. Toki N, Kagami S, Kurita T, et al: Expression of mitochondrial transcription factor A in endometrial carcinomas: clinicopathologic correlations and prognostic significance. Virchows Arch 456: 387-393, 2010.
6. Yoshida Y, Hasegawa Y, Nezu R, et al: Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX. Cancer Sci 102: 578-582, 2011.
7. Kurita T, Izumi H, Kagami S, et al: Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serious ovarian cancer. Cancer Sci 103: 239-244, 2012.
8. Tatarkova Z, Kuka S, Pertás M, et al: Why mitochondria are excellent targets for cancer therapy. Klin Onkol 25: 421-426, 2012.
9. Li X, Zhang G, Luo F, et al: Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep 28: 77-84, 2012.
10. He L, He X, Lim LP, et al: A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134, 2007.
11. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
12. Vingilis A, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
13. Villa C, Fenoglio C, De Riz M, et al: Role of hnRNP-A1 and miR-590-3p in neuronal death: genetics and expression analysis in patients with Alzheimer disease and frontotemporal lobar degeneration. Rejuvenation Res 14: 275-281, 2011.
14. Vinuesa CG, Rigby RJ and Yu D: Logic and extent of miRNA-mediated control of autoimmune gene expression. Int Immunol 20: 112-138, 2009.
15. Hermeking H: MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 12: 613-626, 2012.
16. Papaconstantinou NG, Lykoudis PM, Gazouli M, Manta A, Polymenac G and Voros D: A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma. Pancreas 41: 671-677, 2012.
17. Majid S, Dar AA, Saini S, et al: MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One 7: e46743, 2012.
18. Nordentoft I, Birkenkamp-Demtroder K, Agerbäck M, et al: MicroRNAs associated with chemosensitivity in cell lines and in patients with advanced bladder cancer. BMC Med Genomics 5: 40, 2012.
19. Venneth C, Mourier A, Bezy O, et al: Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice from obesity and insulin resistance. Cell Metab 16: 765-770, 2012.
20. Uchiimi T and Kang D: The role of TFAM-associated proteins in mitochondrial RNA metabolism. Biochim Biophys Acta 1820: 565-570, 2012.
21. Wallace DC and Fan W: The pathophysiology of mitochondrial disease as modeled in the mouse. Genes Dev 23: 1714-1736, 2009.
22. Han B, Izumi H, Yamauchi Y, et al: Human mitochondrial transcription factor A functions in both nuclei and mitochondria and regulates cancer cell growth. Biochem Biophys Res Commun 408: 45-51, 2011.
23. Guo J, Zheng L, Liu W, et al: Frequent truncating mutation of TFAM induces mitochondrial DNA depletion and apoptotic resistance in microsatellite-unstable colorectal cancer. Cancer Res 71: 2978-2987, 2011.
24. Groblewska M, Siewko M, Mroczko B and Szmitkowski M: The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol 50: 12-19, 2012.

25. Rietz A and Spiers J: The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases. Br J Pharmacol 166: 1225-1243, 2012.

26. Mannello F and Medda V: Nuclear localization of matrix metalloproteinases. Prog Histochem Cytochem 47: 27-58, 2012.

27. Bauvois B: New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825: 29-36, 2012.

28. Siefert SA and Sarkar R: Matrix metalloproteinases in vascular physiology and disease. Vascular 20: 210-216, 2012.